Evidence map›Paper›PMID 38014028›Full record

ArticlebioRxiv : the preprint server for biology2023

Exclusion of PD-1 from the immune synapse: a novel strategy to modulate T cell function.

Luke Yi Hao, Shalom Lerrer, Ruijiang Song, Michael Goeckeritz, Xizi Hu, Adam Mor

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Luke Yi Hao
Shalom Lerrer
Ruijiang Song
Michael Goeckeritz
Xizi Hu
Adam Mor
Columbia University Irving Medical Center · US

Funding

Novel mechanisms regulating PD-1 signaling and functionR01AI125640 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Adam Mor · 2016 to 2026
$4.3M
A systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse eventsR01AI175498 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Adam Mor, Robert J Winchester · 2023 to 2026
$2.9M
PAG is a novel target in immunotherapyR01AI150597 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MOR, ADAM · 2020 to 2024
$2.7M
(PQ8) Predictive biomarkers for the onset of immune-related adverse events associated with PD-1 blockadeR21CA231277 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MOR, ADAM · 2019 to 2020
$361k
NCI NIH HHS R21 CA231277NIAID NIH HHS R01 AI125640NIAID NIH HHS R01 AI150597NIAID NIH HHS R01 AI175498
6 · The paper itself

Abstract

Targeting immune checkpoint receptors on T cells is a common cancer treatment strategy. Frequently, this is accomplished through antibodies targeting the ligand of inhibitory co-receptors. Blocking the immune checkpoint PD-1 binding to its ligands PD-L1 and PD-L2 prevents downstream signaling and enhances anti-tumor T cell responses. This approach improved cancer patients' outcome. However, only one-third of the patients respond to these treatments. To better understand the mechanism of anti-PD-1 antibodies, we explored the location of PD-1 within the immune synapse. Surprisingly, we discovered that anti-PD-1 antibodies, besides blocking the interaction between PD-1 and its ligands, also removed PD-1 from the synapse. We demonstrated a correlation between removing PD-1 from the synapse by anti-PD-1 antibodies and the extent of T cell activation. Interestingly, a short version of the anti-PD-1 antibody, F(ab')

Identifiers

PMID38014028
PMCPMC10680742
OpenAlexW4388750634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.